GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nirvana Life Sciences Inc (XCNQ:NIRV) » Definitions » Net-Net Working Capital

Nirvana Life Sciences (XCNQ:NIRV) Net-Net Working Capital : C$-0.02 (As of Jan. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nirvana Life Sciences Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Nirvana Life Sciences's Net-Net Working Capital for the quarter that ended in Jan. 2024 was C$-0.02.

The industry rank for Nirvana Life Sciences's Net-Net Working Capital or its related term are showing as below:

XCNQ:NIRV's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 3.9
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Nirvana Life Sciences Net-Net Working Capital Historical Data

The historical data trend for Nirvana Life Sciences's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nirvana Life Sciences Net-Net Working Capital Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23
Net-Net Working Capital
Get a 7-Day Free Trial -0.02 -0.02 - -0.02 -0.03

Nirvana Life Sciences Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.02 -0.02 -0.02

Competitive Comparison of Nirvana Life Sciences's Net-Net Working Capital

For the Biotechnology subindustry, Nirvana Life Sciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nirvana Life Sciences's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's Price-to-Net-Net-Working-Capital falls into.



Nirvana Life Sciences Net-Net Working Capital Calculation

Nirvana Life Sciences's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Apr. 2023 is calculated as

Net-Net Working Capital(A: Apr. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.012+0.75 * 0+0.5 * 0-1.008
-0--0.003)/34.033
=-0.03

Nirvana Life Sciences's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2024 is calculated as

Net-Net Working Capital(Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.003+0.75 * 0+0.5 * 0-1.029
-0--0.005)/48.233
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Nirvana Life Sciences  (XCNQ:NIRV) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Nirvana Life Sciences Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Nirvana Life Sciences's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Nirvana Life Sciences (XCNQ:NIRV) Business Description

Traded in Other Exchanges
N/A
Address
650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is focused on developing medical products and regimens that address addiction. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.

Nirvana Life Sciences (XCNQ:NIRV) Headlines

No Headlines